Skip to main content
Toggle navigation
Login
Search
Home
Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Favorite
Tweet
Print
Daniel Da Costa, PharmD
Director, Clinical Scientist
Day One Biopharmaceuticals
Poster(s):
(P 08) PRELIMINARY CLINICAL ACTIVITY OF THE TYPE II RAF INHIBITOR TOVORAFENIB IN RAF FUSION-DRIVEN RECURRENT/PROGRESSIVE SARCOMAS
